TrialNature medicine2020

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.

Jianjun Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.